SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (2730)7/22/2019 8:10:18 PM
From: Felix B  Read Replies (2) | Respond to of 3557
 
How much will the SP drop after earnings?



To: Miljenko Zuanic who wrote (2730)7/25/2019 1:58:57 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3557
 
Lucentis 2Q US sale (Roche) are at $467M, flat over 1Q-19, and 10% growth over 2Q-18. Sound good for Eylea-US sale numbers.



To: Miljenko Zuanic who wrote (2730)7/30/2019 10:59:03 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3557
 
Eylea, 2Q ex-US sale (reported by Bayer) are e604 ($676, currency exchange rate is 1.12) is ~12% growth over 2Q-2018, but bit flat over 1Q-2019. My prediction of ~$740M, was on ~1.2 exchange rate, my wrong. Overall 2Q sale are bit disappointment, bayer need to fix their ACT!


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News